Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 25;7(1):00541-2020.
doi: 10.1183/23120541.00541-2020. eCollection 2021 Jan.

Outcomes of COVID-19 patients treated with continuous positive airway pressure outside the intensive care unit

Affiliations

Outcomes of COVID-19 patients treated with continuous positive airway pressure outside the intensive care unit

Rosanna Vaschetto et al. ERJ Open Res. .

Abstract

Aim: We aimed to characterise a large population of coronavirus disease 2019 (COVID-19) patients with moderate-to-severe hypoxaemic acute respiratory failure (ARF) receiving continuous positive airway pressure (CPAP) outside the intensive care unit (ICU), and to ascertain whether the duration of CPAP application increased the risk of mortality for patients requiring intubation.

Methods: In this retrospective, multicentre cohort study, we included adult COVID-19 patients, treated with CPAP outside ICU for hypoxaemic ARF from 1 March to 15 April, 2020. We collected demographic and clinical data, including CPAP therapeutic goal, hospital length of stay and 60-day in-hospital mortality.

Results: The study included 537 patients with a median (interquartile range (IQR) age of 69 (60-76) years. 391 (73%) were male. According to the pre-defined CPAP therapeutic goal, 397 (74%) patients were included in the full treatment subgroup, and 140 (26%) in the do not intubate (DNI) subgroup. Median (IQR) CPAP duration was 4 (1-8) days, while hospital length of stay was 16 (9-27) days. 60-day in-hospital mortality was 34% (95% CI 0.304-0.384%) overall, and 21% (95% CI 0.169-0.249%) and 73% (95% CI 0.648-0.787%) for full treatment and DNI subgroups, respectively. In the full treatment subgroup, in-hospital mortality was 42% (95% CI 0.345-0.488%) for 180 (45%) CPAP failures requiring intubation, and 2% (95% CI 0.008-0.035%) for the remaining 217 (55%) patients who succeeded. Delaying intubation was associated with increased mortality (hazard ratio 1.093, 95% CI 1.010-1.184).

Conclusions: We described a large population of COVID-19 patients treated with CPAP outside ICU. Intubation delay represents a risk factor for mortality. Further investigation is needed for early identification of CPAP failures.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: R. Vaschetto has nothing to disclose. Conflict of interest: F. Barone-Adesi has nothing to disclose. Conflict of interest: F. Racca reports personal fees from Philips Respironics outside the submitted work. Conflict of interest: C. Pissaia has nothing to disclose. Conflict of interest: C. Maestrone has nothing to disclose. Conflict of interest: D. Colombo reports personal fees for lectures from Nestlé Healthcare Nutrition outside the submitted work. Conflict of interest: C. Olivieri has a patent 102016000114357 with royalties paid to Intersurgical SpA. Conflict of interest: N. De Vita has nothing to disclose. Conflict of interest: E. Santangelo has nothing to disclose. Conflict of interest: L. Scotti has nothing to disclose. Conflict of interest: L. Castello has nothing to disclose. Conflict of interest: T. Cena has nothing to disclose. Conflict of interest: M. Taverna has nothing to disclose. Conflict of interest: L. Grillenzoni has nothing to disclose. Conflict of interest: M.A. Moschella has nothing to disclose. Conflict of interest: G. Airoldi has nothing to disclose. Conflict of interest: S. Borrè has nothing to disclose. Conflict of interest: F. Mojoli reports personal fees for lecturing from GE Healthcare, Medical and Seda Spa, outside the submitted work; and a consultancy agreement between University of Pavia and Hamilton Medical. Conflict of interest: F. Della Corte has nothing to disclose. Conflict of interest: M. Baggiani has nothing to disclose. Conflict of interest: S. Baino has nothing to disclose. Conflict of interest: P. Balbo has nothing to disclose. Conflict of interest: S. Bazzano has nothing to disclose. Conflict of interest: V. Bonato has nothing to disclose. Conflict of interest: S. Carbonati has nothing to disclose. Conflict of interest: F. Crimaldi has nothing to disclose. Conflict of interest: V. Daffara has nothing to disclose. Conflict of interest: L. De Col has nothing to disclose. Conflict of interest: M. Maestrone has nothing to disclose. Conflict of interest: M. Malerba has nothing to disclose. Conflict of interest: F. Moroni has nothing to disclose. Conflict of interest: R. Perucca has nothing to disclose. Conflict of interest: M. Pirisi has nothing to disclose. Conflict of interest: V. Rondi has nothing to disclose. Conflict of interest: D. Rosalba has nothing to disclose. Conflict of interest: L. Vanni has nothing to disclose. Conflict of interest: F. Vigone has nothing to disclose. Conflict of interest: P. Navalesi reports personal fees from Intersurgical SpA, Resmed, Philips, Novartis, MSD, Getinge and Orion Pharma, and research equipment (institutional) from Draeger, outside the submitted work; in addition, he has a patent 102020000008305 pending to Università di Padova (no profit) and a patent 102016000114357 with royalties paid to Intersurgical SpA. Conflict of interest: G. Cammarota has nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Cumulative incidence of in-hospital mortality in a) all patients and b) stratified by treatment, i.e. do not intubate (DNI) and full treatment. Data are presented with 95% CI. CPAP: noninvasive continuous positive airway pressure.
FIGURE 2
FIGURE 2
Cumulative incidence of in-hospital mortality in patients requiring invasive mechanical ventilation. Data are presented with 95% CI. ETI: endotracheal intubation.

References

    1. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J 2017; 50: 1602426. doi: 10.1183/13993003.02426-2016 - DOI - PubMed
    1. Masip J, Roque M, Sánchez B, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA 2005; 294: 3124–3130. doi: 10.1001/jama.294.24.3124 - DOI - PubMed
    1. Lemiale V, Mokart D, Resche-Rigon M, et al. Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA 2015; 314: 1711–1719. doi: 10.1001/jama.2015.12402 - DOI - PubMed
    1. Jaber S, Lescot T, Futier E, et al. Effect of noninvasive ventilation on tracheal reintubation among patients with hypoxemic respiratory failure following abdominal surgery: a randomized clinical trial. JAMA 2016; 315: 1345–1353. doi: 10.1001/jama.2016.2706 - DOI - PubMed
    1. Namendys-Silva SA, Hernández-Garay M, Rivero-Sigarroa E. Non-invasive ventilation for critically ill patients with pandemic H1N1 2009 influenza A virus infection. Crit Care 2010; 14: 407. doi: 10.1186/cc8883 - DOI - PMC - PubMed

LinkOut - more resources